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Highlights 
 
x The short QT syndrome (SQTS) is a rare condition associated with atrial and 
ventricular arrhythmias and a risk of sudden death.  Implantable devices and 
antiarrhythmic pharmacology are used to treat the syndrome. 
x There are 8 successfully genotyped variants, involving gain-of-function mutations to 
K
+
 ion channel genes (SQT1-3) or loss-of-function mutations to Ca
2+
 channel subunit 
genes (SQT4-6), to a Na
+
 channel gene (SQT7) and to an anion exchanger (SQT8).    
x Information from patients and in vitro and in silico experiments indicates important 
roles for abbreviated refractoriness, dispersion of repolarisation and a shortened 
wavelength for re-entry in arrhythmia substrates in the SQTS. 
x A combination K+ current inhibition during the action potential plateau, with sodium 
channel inhibition, collectively resulting in delaying repolarisation and refractoriness 
is likely to be valuable in prolonging effective refractory period and wavelength for 
re-entry in the SQTS. In vitro and in silico data point to the feasibility of genotype-
specific pharmacology, though selective agents against each known target are not 
yet in clinical use. 
x Approximately three-quarters of genotyped cases have not yielded mutations in ion 
channel target genes. Exome or genome sequencing may thus be warranted to 
identify the underlying culprits in SQTS cases where targeted ion genotyping is 
unsuccessful. This is likely to reveal new modulators of repolarisation and potentially 
new intervention points to target in the SQTS.  
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Abstract 
 
INTRODUCTION:  Short QT Syndrome (SQTS) is a rare but dangerous condition characterised 
by abbreviated repolarisation, atrial and ventricular arrhythmias and risk of sudden death. 
Implantable cardioverter defibrillators (ICDs) are a first line protection against sudden 
death, but adjunct pharmacology is beneficial and desirable. 
AREAS COVERED: The genetic basis for genotyped SQTS variants (SQT1-SQT8) and evidence 
for arrhythmia substrates from experimental and simulation studies are discussed.  The 
main ion channel/transporter targets for antiarrhythmic pharmacology are considered in 
respect of potential genotype-specific and non-specific treatments for the syndrome. 
EXPERT OPINION:  Potassium channel blockade is valuable for restoring repolarisation and 
QT interval, though genotype-specific limitations exist in the use of some K
+
 channel 
inhibitors. A combination of K
+
 current inhibition during the action potential plateau, with 
sodium channel inhibition that collectively result in delaying repolarisation and post-
repolarisation refractoriness is likely to be valuable in prolonging effective refractory period 
and wavelength for re-entry. Genotype-specific K
+
 channel inhibition is limited by a lack of 
targeted inhibitors in clinical use, though experimentally available selective inhibitors now 
exist. The relatively low proportion of successfully genotyped cases justifies an exome or 
genome sequencing approach, to reveal new mediators and targets, as demonstrated 
recently for SLC4A3 in SQT8. 
 
Abstract:  199 words;  Limit 200 words 
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1. Introduction 
The QT interval of the electrocardiogram (ECG) corresponds to the period from the initiation 
of ventricular depolarisation to completion of ventricular repolarisation. It is well recognised 
that prolongation of the rate-corrected QT (QTc)  interval beyond 440-460 ms (in males and 
females respectively) due either to genetic mutations in ion channels or to pharmacological 
blockade of potassium (K
+
) channels is associated with an increased risk of ventricular 
arrhythmia [1-3].  QTc prolongation beyond 500 ms appears to be particularly associated 
with increased arrhythmia risk [3].  Since 2000, a distinct genetic syndrome involving 
abnormally abbreviated QT intervals (and hence accelerated ventricular repolarisation) has 
been identified [4-6]. Patients with the genetic short QT syndrome (SQTS) typically exhibit: 
abbreviated QT intervals (circa or <320 ms [6]); poor rate-adaptation of the QT interval; tall, 
upright T waves; shortened atrial and ventricular effective refractory periods, and an 
increased risk of ventricular and atrial arrhythmias and of sudden death - in the absence of 
structural heart disease [4;7-10]. Congenital forms of SQTS are distinct from acquired forms 
of QT interval shortening, such as those produced by catecholamines, acetylcholine, 
hypercalcaemia, hyperthermia, cardiac glycosides, carnitine deficiency, or anabolic steroid 
use [11-17]. The present review considers what is known about the underlying basis of SQTS 
and arrhythmogenesis in the syndrome as a platform then to discuss existing and potential 
targets for therapeutic, particularly pharmacological, intervention. 
 
2. tŚĂƚĚĞŶŽƚĞƐĂ “ƐŚŽƌƚ ?YdŝŶƚĞƌǀĂů ? 
Very short QT intervals are rare in the general population. For example, in 10,822 middle-
aged Finnish subjects, only 43 people had a rate-corrected QT interval of <340 ms, and only 
11 people <320 ms [18].  In a large hospital-based population of 114,334, the lowest 0.15 
percentile had QTc intervals of A? 362 and 369 ms for males and females, respectively [19], 
with a biphasic distribution with age (i.e. the shortest QTc intervals in young and old age).   
In a separate study of 18,825 healthy people between 14 and 35, the prevalence of a QTc A? 
320 ms was found to be 0.1% [20].  It is, however, worth noting that the prevalence of short 
QTc intervals may be affected by the rate correction formula adopted for ECG analysis [21]. 
Cohort analysis has highlighted differences in number of individuals meeting SQTS diagnosis 
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criteria between Bazett, Fridericia, Hodges and Framingham rate correction methods [21].   
Whilst congenital forms of SQTS are rare, the risk of sudden death  [9;10;22;23] makes it 
important that congenital SQTS cases are identified and treated.  Diagnostic criteria for the 
SQTS are considered in detail elsewhere [9;20;21;24;25].  Current guidelines from the 
European Society of Cardiology suggest diagnosis of SQTS with a QTc interval of A?340 ms 
[25].  A longer QTc interval of A?360 ms can be used if there is additional evidence of one or 
more of: a familial history of SQTS; a confirmed pathogenic mutation; a family history of 
sudden death below 40 years of age; survival from ventricular tachycardia (VT) or fibrillation 
(VF) in the absence of structural heart disease [25].  Interestingly, PQ segment depression 
has been reported in 52 of a cohort of 64 (>80 %) SQTS patients and may potentially 
constitute an additional marker for the syndrome [26], though further work is required to 
investigate this.  Recently, a refractory period cut-off of 200 ms in the right ventricular 
outflow tract during invasive testing and pacing at basic cycle length of 500  ? 600 ms has 
been proposed as a means of identifying true SQTS from individuals without the syndrome 
who possess borderline QT intervals [27].   
 
3. SQTS genotypes 
In order to consider therapeutic targets for intervention in the SQTS, it is first necessary to 
consider what is known about the underlying genetic basis for the condition.  Inherited SQTS 
mutations are transmitted in an autosomal dominant fashion, with genotyped patients 
being heterozygous for identified mutations [28].    
 
3.1 SQT1 
 
The first study to identify a genetic cause for the SQTS was published in 2004 and implicated 
KCNH2  ĞŶĐŽĚĞĚ “ŚZ' ? ?human Ether-à-go-go-Related Gene) channels in the condition 
[29].  hERG is responsible for the pore-ĨŽƌŵŝŶŐƐƵďƵŶŝƚŽĨŝŽŶĐŚĂŶŶĞůƐƚŚĂƚĐĂƌƌǇƚŚĞ “ƌĂƉŝĚ
ĚĞůĂǇĞĚƌĞĐƚŝĨŝĞƌ ?ƉŽƚĂƐƐŝƵŵĐƵƌƌĞŶƚ, IKr, that plays a key role in regulating cardiac action 
potential duration (APD) [30;31] (Figure 1).  Candidate gene screening was performed in 
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three SQTS families and in two of them nucleotide substitutions were identified in KCNH2 
that led to a common (asparagine to lysine) substitution (N588K) in the external S5-Pore 
linker region of the hERG channel [29].  A subsequent study identified the same mutation in 
another family [32].  Affected individuals exhibited short QT intervals, paroxysmal atrial 
fibrillation (AF), abbreviated atrial and ventricular refractory periods and susceptibility to 
arrhythmia induced by programmed electrical stimulation [29;32].  hERG channels have 
uniquely fast voltage-dependent inactivation that contributes normally to shaping the 
contribution of IKr to ventricular repolarisation [33-36].  The S5-Pore linker region of hERG 
plays a role in hERG current (IhERG) inactivation [37;38].  In initial biophysical characterization 
at ambient temperature, the N588K mutation appeared to eliminate the ability of IhERG to 
inactivate, which would increase greatly the contribution of the current early during the 
ventricular action potential (AP) [29].  Subsequent biophysical analyses, at both ambient and 
physiological temperature, demonstrated that the N588K mutation does not eliminate the 
inactivation process, but profoundly shifts inactivation to more positive voltages, also with a 
modest increase in relative Na/K ion permeability [39;40].  AP voltage clamp experiments 
have shown a profound increase in IhERG during ventricular APs and a shift in timing of peak 
current to earlier in the AP plateau.  Current during atrial and Purkinje fibre APs has also 
been found to be increased for N588K IhERG [39-42].  Simulation studies have demonstrated 
a causal relationship between the mutation and AP and effective refractory period (ERP) 
shortening [43-45].  In 2009, a distinct C terminal hERG mutation (R1135H) was reported in 
a 34 year old male whose ECG showed a mixed Brugada/SQTS phenotype (QTc interval of 
329 ms) [46].  His brother had a QTc of 377 ms and a non-documented arrhythmia, whilst his 
mother had a QTc of 379 ms and exhibited bradycardia.  They also had the R1135H mutation 
[46]. In vitro recordings from R1135H-hERG showed slowed deactivation for this mutant. 
Simulations showed how this could contribute to both abbreviated repolarisation and a 
Brugada phenotype [47].  A third, N terminal, hERG mutation (glutamate Æ aspartate; 
E50D) was reported in 2009 in a 22 year old man who had suffered syncope whilst driving 
[48].  The lowest value of QTc interval duration during Holter monitoring in hospital was 366 
ms and on treadmill testing poor rate adaptation of his ECG was observed [48].  Whilst 
detailed biophysical data on this mutation have not yet been published, a recent article 
refers to unpublished data suggesting that E50D IhERG density is increased compared to that 
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of the WT channel and that deactivation is slowed and inactivation modestly positive-shifted 
[49].  
The T618I-hERG, mutation, which occurs at a highly conserved site in the pore-loop of the 
hERG channel, was originally found in a male whose father and 2 sisters had been victims of 
sudden death [50]. He had a QTc interval of 298 ms, reduced rate-adaptation of the QT 
interval and a markedly shortened ERP, all in the absence of structural abnormalities of the 
heart. Programmed electrical stimulation induced VT/VF [50]. Affected offspring also had 
QTc intervals of <320 ms.  This mutation has now been identified in 7 unrelated, 
geographically dispersed (Europe, USA, Canada, China, Japan) families [49], with a mean QTc 
interval for probands and other carriers of 313 ms, poor rate adaptation of the QTc interval, 
tall peaked T-waves, no gender preference in terms of carriers and 100% penetrance [49]. 
Affected families have a high incidence of sudden death and aborted sudden death [49].  A 
distinct U wave has been reported to be present in precordial leads of ~70 % of carriers. 
Interestingly, similar to N588K hERG, T618I carriers are vulnerable to VT and VF; however, in 
contrast to N588K hERG, no reported T618I probands or carriers have experienced AF (cf. 
60% probands for N588K hERG) [49].  This mutation has been established to be the most 
common clinically occurring mutation of any SQTS variant (accounting for 25.9% of 
genotyped probands, with N588K the second most commonly occurring at  18.5% [49]).   
Biophysical analysis of T618I-hERG at room temperature showed a marked increase in 
current during depolarising voltage commands, accompanied by reduced I-V relation 
rectification, a negative shift in voltage-dependent activation, accelerated deactivation, a 
positive shift in voltage-dependent IhERG inactivation, slowed development of inactivation 
but accelerated recovery from inactivation [50].  At 37
o
C, however, a +15 mV positive shift in 
voltage dependent activation, no change in rate of activation, but significantly accelerated 
deactivation,  a moderate positive shift in voltage dependent inactivation and slowed rate of 
onset of inactivation were seen [51] ?sĞŶƚƌŝĐƵůĂƌ “WĐůĂŵƉ ?Ăƚ ? ?oC showed a marked 
positive shift in peak current during the AP and a near-doubling of peak current during 
repolarisation [51]. A very recent study with room temperature recordings [49] has reported 
a negative voltage shift in activation for T618I hERG, accelerated time-course of activation 
(changes not seen at 37
o
C [51]) and did not report data for inactivation [49].  In short, whilst 
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T618I is clearly a gain-of-function mutation, the precise mechanisms underlying this effect 
appear to differ between studies and recording conditions.     
In 2015 a 64 year old man with paroxysmal AF and atrial flutter was diagnosed with SQTS 
(QTc interval of 319 ms and peaked T waves on the precordial leads).  His father and brother 
had died suddenly. Genetic testing uncovered an isoleucine to threonine mutation (I560T) in 
the transmembrane segment of the hERG channel [52].  In vitro analysis of I560T IhERG 
revealed an increase in IhERG magnitude, without changes to voltage-dependent activation, 
but with a modest positive shift in voltage-dependent inactivation of the current [52]. 
Computer simulations confirmed that these changes could result in abbreviated 
repolarisation [52]. In 2017, a link was established between a pore serine to alanine 
mutation (S631A) and SQTS [53].  The S631A mutation had been studied in vitro previously 
as an experimental mutation to impair hERG inactivation [54], profoundly positively-shifting 
the inactivation process [55] and producing an alteration to IhERG during the ventricular AP 
[36] akin to that seen for N588K [39;40]. This mutation has now been identified clinically for 
the first time, in a family with abbreviated QT intervals and history of sudden death [53]. 
The index patient exhibited a QTc interval of <320 ms at age 6 and 323 ms at age 18.  Her 
younger sister had a QTc interval of 340 ms and slightly reduced ejection fraction (42%, MR 
tomography).  Her father had a QTc of 324 ms, whilst an asymptomatic dizygotic twin 
brother had no QT interval shortening [53]. Both the index patient and her asymptomatic 
mother possessed and additional SCN10A mutation, but as this was absent from other 
affected individuals it was unlikely to be causative of the SQTS phenotype.  
 
3.2 SQT2 
SQT2 results from mutations to KCNQ1, which encodes the pore-forming subunit of IKs (slow 
delayed rectifier) potassium channels (the KCNQ1 protein combining with KCNE1 to form 
functional proteins [31]) (Figure 1). The first identified form of SQT2 resulted from a 
mutation (V307L) in the pore-helix (P-loop) of KCNQ1, which is  associated with left-ward 
voltage-shifted and faster time-dependent activation and slower deactivation of IKs 
(KCNQ1+KCNE1 channels) [56;57].  The 70 year old male  patient in whom the mutation was 
identified experienced aborted sudden death (VF) and abbreviated ventricular 
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repolarisation with a QTc interval of 302 ms [56]. Simulation data have verified a causal link 
between this mutation and QT interval shortening and susceptibility to ventricular 
arrhythmia [58;59].  A second variant was observed in utero, with bradycardia and irregular 
rhythm and ECG analysis showing abbreviated QT interval and episodes of AF [60]. Genetic 
analysis revealed a de novo mutation in the S1 transmembrane domain of the KCNQ1 
protein (V141M). Biophysical analysis of this mutation revealed that the mutation induced 
an instantaneous component of KCNQ1+KCNE1 current that was absent in wild-type (WT) 
channels [60]. Simulation data confirmed that this mutation can prolong QT interval and 
slow pacemaker rate [60;61].  The R295H mutation was found in a 20 year old proband with 
a QTc interval of 310 ms who had undergone aborted cardiac arrest [62].  His mother 
possessed the same mutation and a QTc interval of 300 ms and had experienced paroxysmal 
VT.  Biophysical analysis showed increased current density, faster activation kinetics and 
slowed deactivation kinetics for IKs (KCNQ1+KCNE1) channels incorporating the R295H 
mutation [62]. The F279I KCNQ1 mutation was identified in the 23 year old son of a 37 year 
old man who had died suddenly [63] ?dŚĞƐŽŶ ?Ɛ'ƐŚŽǁĞĚƐŝŶƵƐďƌĂĚǇĐĂƌĚŝĂ ?ƉƌŽŵŝŶĞŶƚd
waves in V2-V4 and a QTc interval of 356 ms, shortening to 350 ms under an exercise load.  
The F279I mutation resides in the S5 transmembrane segment of the KCNQ1 protein and 
resulted in KCNQ1+KCNE1 current that exhibited a negative shift in voltage dependent 
activation and accelerated activation kinetics and the interaction between KCNQ1 and 
KCNE1 was impaired for mutant channels [63].  Computer simulations demonstrated a 
causal relationship between the F279I mutation and accelerated repolarisation [63]. 
 
3.3 SQT3 
SQT3 results from mutations to the KCNJ2 gene that encodes the Kir2.1 protein.  Kir2.1 
contributes to inwardly rectifying (IK1) K
+
 channels that set the resting potential in non-
pacemaker cells and that contribute to action potential terminal repolarisation [31;64] 
(Figure 1).  The first SQT3 mutation was found in an asymptomatic 5 year old girl with a 
markedly abbreviated QT interval and tall, asymmetric T-waves; her father had a history of 
lamenting tachycardia and palpitations [65]. This form of the SQTS was linked to a mutation 
(D172N) in KCNJ2-encoded Kir2.1 [65]. The affected residue resides in the transmembrane 
pore of Kir2.1 and is involved in the Mg
2+
 and polyamine block that underpins voltage-
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dependent rectification of IK1 [65;66]. In D172N-Kir2.1 channels, this process appears 
impaired, consequently leading to augmentation of outward but not inward current [65;67].  
Simulations showed that the changes to IK1  consequent to this mutation would accelerate 
the final stages of ventricular repolarisation and abbreviate AP duration, though to a lesser 
extent than the V307L KCNQ1 or N588K hERG mutations [65]. The abrupt abbreviation of 
the final stage of repolarisation accounted for the asymmetric T waves seen clinically [65]. 
The authors of the study that identified D172N-Kir2.1-ůŝŶŬĞĚ^YdĐŽŵŵĞŶƚĞĚƚŚĂƚ “ƚŚĞ
D172N mutation creates a vulnerable substrate that may facilitate development of atrial 
ĂŶĚǀĞŶƚƌŝĐƵůĂƌƚĂĐŚǇĂƌƌŚǇƚŚŵŝĂƐĞǀĞŶŝŶĂŚĞƚĞƌŽǌǇŐŽƚĞƐƵďƐƚƌĂƚĞ ? ?[65]. Subsequent 
action potential voltage-clamp experiments showed that the mutation augments Kir2.1 
current during both ventricular and atrial APs [67] and simulations have shown how the 
mutation can produce a substrate for ventricular arrhythmia [68]. A second SQT3 KCNJ2 
(M301K-Kir2.1) mutation was identified in an 8 year old girl with a markedly shortened QTc 
interval (194 ms), who suffered from paroxysmal AF [69].  When expressed alone, M301K 
channels did not pass current, but when co-expressed with WT channels (mimicking the 
heterozygous state of the proband), the inward rectification properties of Kir2.1 were 
markedly impaired, leading to significantly greater current over physiological repolarisation 
voltages [69]. A third SQT3 mutation to KCNJ2 (E299V-Kir2.1 reported in 2013) results in a 
more profound lack of inward rectification of Kir2.1 current compared to the M301K-Kir2.1 
mutation [70] and simulations showed it to produce a much more marked AP abbreviation 
compared to the D172N mutation [70].   
 
3.4 SQT4 and SQT5 
SQT4 and SQT5 involve mutations to subunits that comprise channels mediating L-type Ca
2+
 
current (ICa,L) (Figure 1).   82 probands with Brugada syndrome were screened for ion 
channel mutations and 7 were identified with mutations to the D ĂŶĚɴ2b subunits of L-type 
channels; of these 7, 3 exhibited QTc intervals of 360 ms or less [71].  The first proband was 
a 25 year old male who presented with aborted sudden cardiac death. He had a QTc interval 
of 330 ms and coved ST-segment elevation in V1 and V2 ECG leads. A total of 6 of 10 family 
members showed ST-elevation and somewhat abbreviated QTc intervals [71].  He (and other 
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phenotype-positive family members) showed a CACNB2b mutation absent in 400 ethnically 
matched control alleles, that led to a S481L substitution in the CACNB2b protein [71].   The 
second proband was a 41 year old male who presented with AF and a QTc interval of 346 
ms.  His brother had died of sudden cardiac arrest at 45 yrs. of age  [71]. The QT interval 
showed poor rate dependence and ST segment elevation in ECG leads V1 and V2 was 
enhanced with ajmaline.  There was no structural heart disease but monomorphic VT could 
be elicited by programmed electrical stimulation.  He had a mutation of CACNA1C, which led 
to a G490R substitution in the Cav1.2 protein, but absent in 640 ethnically matched control 
alleles.  His 2 daughters also possessed the mutation and shortened QTc intervals.  He 
possessed additional polymorphisms (P1280L and V1821M) that were found in healthy 
controls and so unlikely to be causally linked with his pathology [71].  The third proband was 
a 44 year old male with prominent ST elevation in V1 and saddleback ST elevation in V2 and a 
QTc interval of 360 ms. His mother had died suddenly at 48.  He had a CACNA1C mutation 
that led to an A39V mutation in Cav 1.2.   In biophysical experiments, all three mutations led 
to marked reductions in ICa,L.  The loss of current with the A39V mutation (but not the other 
two) was associated with a reduction of surface expression, consistent with a trafficking 
defect [71].  All three mutations were thus loss of function mutations that led to a mixed 
Brugada/SQTS  phenotype.  In a more recent study a distinct CACNA1C mutation (leading to 
a R1937P mutation in Cav1.2) has been identified in a 52 year old male with an early-
repolarisation pattern ECG and QTC of 356 ms [72;73].  He suffered from atrioventricular 
block and severe left ventricular hypertrophy and dysfunction and possessed 2 additional, 
distinct mutations (E234K in desmin, DES; R989H in myopallidin, MYPN) that also likely 
contributed to his overall pathology.  His daughter also possessed all mutations, though with 
a milder phenotype.  In functional analysis, R1937P channels showed a marked loss-of-
function [72]. 
 
3.5 SQT6 
SQT6 was identified from a 17 year old female who suddenly lost consciousness in church. 
Ventricular fibrillation was terminated by defibrillation. In hospital, her ECG was found to 
exhibit a short QTc interval (329 ms) and tall, narrow T waves [74]. Programmed electrical 
stimulation could elicit AF and VT. Genetic screening revealed a S755T substitution in the 
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CACNA2D1 encoded CavD2ɷ-1 subunit of the L-type Ca2+ channel.  Coexpression of the 
mutant CavD2ɷ-1 subunit with Cav ? ? ?ɲ ?ĂŶĚĂvɴ2b led to reduced ICa,L (using Ba2+ ions as 
charge carrier) compared to the WT control, without an obvious effect on surface 
expression, suggestive of a modification of single channel properties by the S755T CavD2ɷ-1 
[74]. 
 
3.6 SQT7 
In 2012, a novel mixed SQT/Brugada phenotype was identified that is caused by a missense 
mutation to the SCN5A gene, which encodes the ɲsubunit of channels carrying cardiac 
sodium current, INa [75] (Figure 1).  A 40 year old man was admitted to hospital for a non-
cardiac injury and was found to have a Brugada-like ECG, accompanied by a short QT 
interval (QT of 320 ms at 71 beats min
-1
). His father had died suddenly at age 39.   An R689H 
mutation was identified in SCN5A; biophysical analysis showed that SCN5A protein 
incorporating the R689H mutation was unable to mediate INa, indicating loss of function 
[75].  As INa mediates the ventricular action potential upstroke and can influence APD via a 
late current component, the loss of function associated with R689H could affect both 
conduction and repolarisation.  The authors of this study discussed the fact that the R689H 
mutation had previously been associated with a long QT phenotype and noted the potential 
for some genetic defects to have different phenotypic manifestations [75].  A subsequent 
experimental study reported the R689H mutation to increase late INa [76], which raises a 
question as to whether or not the mutation is able on its own to account for a SQT 
phenotype. 
 
3.7 SQT8 
Candidate ion channel screening has resulted in positive genotyping in <30% of SQTS cases 
[9].  Exome or genome sequencing can thus be predicted to uncover novel, unexpected 
genetic associations with SQTS.  This is well-illustrated by the discovery in 2017 of a new 
SQTS variant, found in 2 unrelated families that possess mutations in the anion exchanger 
(AE3) gene SLC4A3 [77].  The index patient from the first family presented at 31 years of age 
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with cardiac arrest during sleep followed by an episode of VF in hospital.  He had a QTc 
interval duration of 320 ms in the absence of structural heart disease. Four relatives had 
experienced episodes of syncope in their second decade; two had died suddenly at 41 and 
42 years of age [77].   In the second family, the proband died at the age of 22 at rest. His 
brother had a structurally normal heart, but a QTc interval of 320 ms. Two further relatives 
had short QTc intervals [77]. Normal gene panel screening revealed no mutations in 
candidate ion channels. However, exome screening of six SQTS individuals and 5 healthy 
controls revealed a missense variant in SLC4A3, leading to the R370H mutation in a 
conserved motif of the SLC4 family [77].  Cascade screening identified other carriers of the 
mutation who had a mean QTc lower than non-carriers [77].  Expression studies of 
recombinant wild-type and mutant AE3 showed the mutant form to have reduced surface 
localization, suggestive of impaired trafficking.  HCO3
-
 transport was impaired in cells 
expressing the mutant form of AE3.  Knockdown of slc4a3 in zebrafish embryos replicated 
QTc shortening and also resulted in raised intracellular pH in zebrafish embryo hearts [77]. 
Finally, intracellular alkalization and reduced intracellular chloride concentration ([Cl
-
]i) 
abbreviated repolarisation in rabbit hearts [77] .  Collectively, these observations suggest 
that intracellular alkalization and reduced [Cl
-
]i as a result of the R370H AE3 mutation 
contribute to accelerated repolarisation in this form of SQTS [77].  The processes affected by 
these changes to effect faster repolarisation remain to be elucidated. 
Table 1 summarises known mutations in SQT1-SQT8. 
 
4. Arrhythmia mechanisms 
There are no genotypically accurate mammalian models of the SQTS. Information on 
underlying arrhythmia mechanisms in the syndrome has been gleaned from studies using in 
vitro preparations and potassium channel activators and also from computer modelling 
based on changes to ion channel properties seen in recombinant channel experiments.  The 
KATP channel activator pinacidil produces a short QT phenotype when applied to canine left 
ventricular wedge preparations or to intact rabbit hearts [78-80].  Pinacidil was seen to 
produce heterogeneous APD abbreviation across the canine left ventricular wall and thus 
augment transmural dispersion of repolarisation (TDR) and increase susceptibility to 
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provoked polymorphic VT [78].  In intact rabbit hearts, pinacidil abbreviated QT interval and 
ERP, which was associated with increased susceptibility to VF [79;80].  Application of the 
hERG/IKr activator PD118057 to canine left ventricular wedge preparations to mimic SQT1 
abbreviated QT interval and ERP and augmented TDR and arrhythmia susceptibility [81]. 
Enhanced TDR has been seen in SQTS patients [82].  Multilevel modelling of N588K-linked 
SQT1 has shown reductions in APD and ERP, with localised increases in maximal ventricular 
transmural voltage heterogeneity (ɷs ?ŝŶƚŚĞ^Yd ?ƐĞƚƚŝŶŐ ?ŝŶĐƌĞĂƐŝŶŐǀƵůŶĞƌĂďŝůŝƚǇƚŽ
unidirectional conduction block [45].  A reduced ventricular substrate size needed to sustain 
re-entry facilitated spiral and scroll wave lifespan/stability in 2D and 3D simulations [45].  
Parallel observations have been made in simulations of SQT2 [58;59].  Biophysical modelling 
has also confirmed the ventricular proarrhythmic nature of KCNJ2 SQTS mutations 
[65;68;70]. For example, D172N Kir2.1 leads to abbreviated APD and ERP and to steeper 
restitution curves for these parameters [68].  The D172N mutation reduces tissue 
excitability at slow rates but increases it at higher ones, also increasing temporal 
vulnerability to initiation of re-entry whilst reducing the substrate size required to maintain 
re-entry [45]. 
Heterogeneous effects of SQT mutations on the magnitude of repolarising current during 
ventricular and Purkinje fibre APs have been observed and the possibility raised that these 
may contribute to the pronounced U waves reported in some SQTS patients [39;41]. 
However, it is very probable that altered electromechanical coupling is likely to be of 
principal importance in this regard: echocardiographic analysis has revealed a dissociation 
between the end of mechanical systole and ventricular repolarisation in SQTS patients [83]. 
In SQTS the U wave was found to coincide with the end of mechanical systole and beginning 
of isovolumetric relaxation [83].  The corresponding electrical changes that contribute to the 
U wave were not established, but may involve delayed after-depolarisations or early phase 3 
afterdepolarisations [84].  A combination of Doppler imaging and speckle-tracking 
echocardiography has revealed a modest decrease in left ventricular contraction and 
increased mechanical dispersion in SQTS patients [85;86]. In silico simulations predict a 
reduced systolic Ca
2+
 transient and contraction in models incorporating SQT mutant K
+
 
channels [87;88] and, consistent with this, a modest reduction in ventricular myocyte 
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shortening accompanies AP abbreviation with the hERG/IKr activator PD118057 to mimic 
SQTS  (Figure 2A). 
A proportion of SQTS patients exhibit AF [22;23;52]: approximately 63% of SQT2 patients 
and 21% of non-SQT2 patients [52].  Experiments on a perfused canine atrial preparation, 
using PD118057 to mimic a SQT phenotype have shown AP and ERP abbreviation and an 
increase in spatial dispersion of repolarisation, which collectively increased susceptibility to 
AF induced by premature stimulation [89].  In silico investigation of the SQT1 N588K 
mutation found this to decrease ERP and re-entry wavelength (WL) [90].  Our own 
simulations of the D172N and E299V SQT3 Kir2.1 mutations found both to decrease re-entry 
WL through reducing ERP and conduction velocity [91]. However, the two mutations, which 
produce qualitatively different effects on IK1 differentially affected spatial dispersion of APD 
(with D172N producing increased spatial heterogeneities in some regions and E299V 
reducing global dispersion of repolarisation), with consequences for stability of re-entry in 
the two situations (D172N resulting in greater re-entry stability) [91].   
Harrell and colleagues investigated genotype-specific characteristics amongst 65 genotyped 
individuals [52].  The mean age of manifestation appears to be significantly later for SQT1 
patients (35 yrs) than for SQT2 (17 yrs) and SQT3-6 ( 19 yrs), whilst QTc intervals are 
comparable.  In this study, non-genotyped patients had a mean age of manifestation of 28 
yrs. Sick sinus syndrome/ bradyarrhythmia appears particularly prominent in SQT2 (75% of 
SQT2 versus 9% non-SQT2 patients [52]) and this may involve IKs with KCNQ1 mutations 
(particularly V141M) stabilising membrane potential/resisting diastolic depolarization in 
sinus node cells ([60], Whittaker et al, unpublished).  Aside from these features and the 
greater proportion of SQT2 patients with AF, other clinical characteristics were not seen to 
differ between genotypes [52].  Thirteen families with SQT1-3 showed a penetrance of 90% 
compared to 58% for SQT4-6 [52]. The N588K and T618I hERG SQT1 mutations have been 
reported to exhibit 100% penetrance [49]. 
General arrhythmia mechanisms in SQTS are summarised in Figure 2B. 
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5. Therapeutic strategies and options 
The SQTS carries a high risk of sudden death, with a >40% probability of a cardiac arrest by 
the age of 41 years, of 4% during the first year of life alone and of 1.3% per year between 20 
and 40 [92]. Documented cardiac arrest events appear to be particularly common at rest, 
during sleep or undemanding routine activities [92].  Unsurprisingly, therefore, the primary 
treatment for SQTS patients is the use of implantable defibrillator devices (ICDs; 
[8;23;93;94]).  The changes in T wave morphology in the SQTS can pose a challenge to ICD 
use, however, in that there is a recognised risk of inappropriate shocks due to T wave 
oversensing in SQTS patients [8;23;93;95].  Moreover, the incidence of inappropriate ICD 
shocks has been observed to be significantly higher in paediatric SQTS patients than in an 
adult cohort [24], indicating a particular challenge in the use of ICD devices in young 
patients.  Whilst such issues can be addressed through ICD reprogramming [93], ICDs do not 
normalize repolarisation or the arrhythmogenic substrate(s) per se and so there is a strong 
case for the use of adjunct pharmacological approaches.  
 
5.1  IKr blockade 
IKr block is predominantly responsible for repolarisation delaying actions of many class Ia 
and III antiarrhythmic drugs and underpins entirely the actions of methanesulphonanilide 
class III drugs, including dofetilide and sotalol [96;97]. In the initial study that identified 
N588K-hERG linked SQT1, sotalol was administered, but did not restore the QTc interval 
towards normal [29].  A number of antiarrhythmic drugs were tested in a subsequent study 
(sotalol, ibutilide, flecainide, hydroquinidine) but only hydroquinidine was found to be 
successful at prolonging QTc interval, ventricular ERP and protecting against VF [32].  The 
reason for the difference in effectiveness between sotalol and quinidine could in principle 
involve effects of quinidine on additional targets than IKr and/or differences in effects of the 
N588K mutation on HERG/IKr sensitivity to the drug: evidence in support of the latter comes 
from the observation that the IC50 for IhERG block by sotalol was increased by ~20-fold 
compared to ~5.8 fold for quinidine [98].   The basis for this difference is likely to reside in 
the inactivation-dependency of block by the two compounds: hERG block by 
methanesulphonanilide class III agents is known to depend strongly, directly or indirectly, on 
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hERG channel inactivation gating [99-102].  Quinidine is much less dependent on channel 
inactivation for binding to hERG to occur [99;103].  Consistent with this, the class Ia drug 
disopyramide is also comparatively less dependent on inactivation to bind to hERG [104] 
and when tested against N588K-hERG showed an IC50 only 1.5-fold that of the WT channel 
[105].  In direct comparison, the methanesulphonanilide E-4031 showed an IC50  against 
N588K-hERG 11.5-fold that of the WT channel [105].  Like quinidine, disopyramide has been 
found to exert beneficial effects in SQT1 patients on QTc interval, its rate dependence and 
on ventricular ERP [106].   It has also been found to be effective in a patient with SQTS of 
unknown genotype [107].  In the ventricular wedge model of SQT1 induced by IKr activation 
with PD118057,  quinidine was found to prolong QT interval and ERP without altering TDR 
[81]. Originally, it was proposed that the additional IKs blocking action of quinidine might 
contribute to its efficacy in SQT1 [29;108].  Recent computational analysis of actions of both 
quinidine and disopyramide on human ventricular electrophysiology in the setting of N588K-
linked SQT1, incorporating their known actions and kinetics on IKr and INa, as well as effects 
on other known targets, has demonstrated that beneficial effects on the QT interval are 
mostly due to their IKr blocking effect, whilst prolongation of the ERP derives from a 
combination of effects on IKr and INa [109].  Thus, for the most severe SQT1 phenotypes 
(which involve the greatest impairment to hERG/IKr channel inactivation) IKr inhibitors that 
do not depend strongly on the process of channel inactivation for binding should, in 
principle, be effective, particularly when combined with a class Ia type antiarrhythmic 
action.  Consistent with this, in a canine right atrial experimental model of SQT1, combined 
IKr and INa block but neither action alone was effective at preventing AF [89].  
The likely effectiveness of IKr block in other types of SQTS can be inferred from the important 
role IKr normally plays in repolarisation and the fact that the kinetics of IKr, and hence drug 
binding, should be intact in non-SQT1 forms of the syndrome.  Consistent with this, drugs 
with IKr-blocking properties have been reported to be effective in pinacidil-induced SQTS 
models [78-80] and in patients with non-SQT1 forms of the syndrome (e.g. [22;71]).   
Indeed, comparison of SQT1 and non-SQT1 forms of the syndrome suggests efficacy of 
quinidine in both settings, but with greater effects in SQT1 patients [22].  Our simulation 
work on SQT3 suggests that IKr block is likely to be beneficial against both D172N and E299V 
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Kir2.1 mutations when combined with inhibition of the ultrarapid IK current, IKur, and also on 
its own against E299V [91]. 
One cautionary note in respect of IhERG/IKr block is that whilst in vitro data on T618I hERG 
have pointed towards effectiveness of a range of drugs with IKr inhibitory effects including 
both sotalol and quindine [50;51],  these in vitro predictions have not translated universally 
to patients.  Thus, sotalol has been tried but found to be ineffective at prolonging QTc 
interval in T618I carriers [49;110].  Quinidine has been found to prolong QTc interval but not 
to prevent arrhythmias in all  T618I patients receiving it [49].  Bepridil, which has not been 
tested in vitro against T618I hERG, has been found to be effective in a T618I patient with VF 
refractory to other treatment [49].  Further work is required to understand the deviation 
between experimental and in vivo pharmacology in respect of T618I hERG SQT1 carriers. 
 
5.2 IKs blockade 
In principle, IKs inhibition could have value in the treatment of both SQT2 and non-SQT2 
SQTS variants.  The V307 residue lies in a region of the KCNQ1 protein that has been 
identified to be the interaction site for canonical (chromanol-based) IKs inhibitors, and the 
V307L SQT2 mutation significantly reduces potency of inhibition by chromanol 293B [111]. 
By contrast, mefloquine, which may not actually require channel gating for binding to occur 
[112], was found to be effective at inhibiting recombinant IKs channels incorporating the 
V307L mutation [57].  By contrast with V307L, the V141M mutation has been reported to 
show increased sensitivity to the IKs inhibitor HMR-1556, as has a proximate heritable AF 
gain-of-function mutation S140G [113].  In recent in silico simulations, modelling ~60% 
inhibition of IKs was required to normalize repolarisation in the setting of heterozygous 
V307L mutation, whilst in 3D ventricle simulations 58% IKs inhibition was able to normalize 
the lifespan of re-entry in the heterozygous V307L condition to that in the WT condition 
[59].  Taking together the available information, IKs inhibition is predicted to be an effective 
strategy in SQT2, with the efficacy in practice depending on the location of SQT2 mutations 
relative to drug binding site(s).  The overall importance of IKs to repolarisation reserve [114] 
might suggest a role for IKs block in other SQTS variants, though the degree to which IKs is 
recruited during abbreviated APs might be reduced and hence provide reduced potential for 
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AP prolongation.  At present, selective IKs inhibition remains a theoretical treatment 
possibility, as there are no selective IKs inhibitors in clinical use. 
 
5.3 Ito blockade 
For SQTS variants with a mixed SQTS/Brugada phenotype, selective Ito (transient outward 
potassium current) block could be useful in correcting early repolarisation [28].   Selective Ito 
inhibitors are not clinically available, though quinidine inhibits Ito as well as IKr and INa [31] 
and was successful in treating an SQT4 patient [71]. Vernakalant, which combines Ito and INa 
block with actions on IKr and IKur has been found to suppress VF in a pinacidil model of SQTS 
[79]. 
 
5.4 IK1 blockade 
Unlike IKr and IKs channels, those mediating IK1 normally carry little current over the 
ventricular AP plateau phase, with the principal repolarisation contribution of IK1 being 
during terminal repolarisation [31;115].  It is possible, therefore, that IK1 block might not be 
an optimal target for APD/QT interval prolongation in non-SQT3 forms of the SQTS.  For 
SQT3, on the other hand, IK1 could represent a genotype-specific target.  There are no 
selective IK1 inhibitors in clinical use, but the antimalarial drug chloroquine has been found 
to be an effective inhibitor of D172N Kir2.1 and to normalise ventricular repolarisation and 
to prolong ventricular ERP in silico in the D172N-linked SQT3 variant [67;116;117].  
Additional inhibitory effects on IKr ŵĂǇƐƵƉƉůĞŵĞŶƚƚŚĞĚƌƵŐ ?ƐĂĐƚŝŽŶƐŽŶIK1 [116;117].  
Chloroquine binds in the cytoplasmic pore of Kir2.1 [118] and the M301A mutation was not 
found to impair chloroquine block and so it is likely that M301K mutant channels would 
retain drug sensitivity [118].  On the other hand, the E299A mutation significantly impaired 
chloroquine block [118], so E299V channels might not retain WT channel sensitivity to 
chloroquine.  Recently, a pentamadine analogue, PA-6, has been identified that inhibits 
Kir2.1 selectively at submicromolar concentrations [119].  It has been shown also to be able 
to inhibit D172N Kir2.1, albeit with a modest reduction in potency [120]. PA-6 exerts an 
agonist effect on Kir2.1 protein expression, but this action is likely to be outweighed by its 
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acute channel blocking effect [120].  The encouraging in vitro results with PA-6 point 
towards the potential for selective IK1 inhibitors in SQT3.   Our atrial electrophysiology in 
silico modelling results with SQT3 mutants found a 50% reduction in IK1 to be insufficient to 
terminate re-entry for D172N conditions, but this was sufficient to prevent sustained re-
entry for E299V conditions [91]. For both mutants, the simulated combination of IK1 +IKr was 
effective at terminating re-entry, indicating synergistic effects of combining the two actions 
[91]. 
  
5.5 L-type Ca channel activation 
In simulations of atrial effects of SQT3 mutations, increasing ICa,L by 100% decreased the 
dominant frequency of atrial re-entrant excitation but failed to terminate re-entry.  An 
increase to 250% was sufficient to terminate atrial re-entry [91].  However, neither atrial 
electromechanical coupling nor ventricular consequences of such a large increase in ICa,L 
were considered. In principle, abbreviated repolarisation in SQT4-6, involving reductions to 
ICa,L  could be rectified by pharmacological augmentation of ICa,L, but (i) selective agonists of 
ICa,L are not available clinically, (ii) augmentation of ICa,L beyond required levels may be 
proarrhythmic, and (iii) ICa,L agonism may also produce extracardiac side effects.   
 
5.6 AE3 activation 
The recent discovery of impaired AE3 function in SQT8 highlights a potential new target for 
treatment, at least in this variant of the SQTS [77].  However, there is no current 
pharmacological approach that could restore normal function of mutant AE3.  AE3
-/-
 
knockout mice have been reported to have similar cardiac function to WT controls at 
baseline [121;122] and, whilst steady-state pHi was reported to be similar between WT and 
AE3
-/-
 cardiomyocytes, the knockout myocytes were slower to recover from induced 
alkalosis [122].  Repolarisation mechanisms differ markedly between mouse and human, 
however, making mice unsuitable to explore AE3 in the context of SQTS. Given the 
promising initial results using zebrafish embryos [77] and the comparatively human-like 
ventricular action potentials of adult zebrafish [123], this species would likely be of 
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significant value to explore the consequences of mutant AE3 in SQT8.  There is potential 
utility in further research to establish the downstream targets that mediate delayed 
repolarisation in this setting, as this may identify alternative intervention points.  
 
6. Expert Opinion 
The existence, at the time of writing, of eight distinct SQTS genotypes firmly establishes the 
SQTS as a primary genetic syndrome.  The relatively low proportion (approximately 1 in 4 
tested [124]) of successfully genotyped cases makes it important to differentiate clearly 
congenital from acquired causes of the syndrome and that any potential acquired causes  
(including hypercalcaemia, cardiac glycoside, anabolic steroid use [11-17]) are eliminated 
from the picture (and treated, where necessary) during diagnosis.  SQTS as a consequence 
of carnitine deficiency has been associated with mutations to the SLC22A5 gene that 
encodes the OCTN2 carnitine transporter [17] and so, arguably, SQTS could be considered to 
be secondary to SLC22A5 mutations in such cases.  Mice with induced carnitine deficiency 
showed both structural remodelling and abbreviated ventricular repolarization, 
substantiating a causal link [17].  Where carnitine deficiency associated SQTS is observed 
dietary carnitine supplementation may be beneficial [17].  The poor rate adaptation of the 
QT interval in congenital SQTS patients makes cases likely to be more apparent on ECGs at 
low/resting heart rates [124] and the presence of mixed Brugada-SQTS phenotypes in some 
SQT variants, together with evidence for a high prevalence (~65%) of early-repolarisation in 
SQTS patients [125] ?ŵĞĂŶƐƚŚĂƚŝŶƐŽŵĞŝŶƐƚĂŶĐĞƐ^Yd^ŵĂǇĞǆŝƐƚĂƐĂŶ ‘ŽǀĞƌůĂƉ ?ƐǇŶĚƌŽŵĞ ? 
Given the potential for differences in calculated QTc interval to arise dependent on the rate 
correction method used [21], and as highlighted by the authors of [21], to mitigate such 
issues it is important that ECG measurements are repeated in individuals with suspected 
SQTS at rates as close to 60 beats min
-1
 as possible. 
On the basis of the in vitro and in silico evidence considered above, at least in respect of K
+
 
channel-linked variants, genotype-specific pharmacology to restore normal repolarisation is 
possible.  In practice, however, this is limited by the fact that entirely selective inhibitors of 
IKs and IK1 are not yet clinically available and that for SQT1 variants with severe inactivation-
lesions, purely IKr-selective compounds (methanesulphonanilides) may not be effective.  
EOTT-2018-0017 Revised 
 
22 
 
Pharmacological strategies selectively to increase ICa,L
 
are not clinically available and are 
potentially fraught with issues of extra-cardiac side effects and, potentially, of 
proarrhythmia.  Further work is probably warranted to determine whether atrial-selective 
strategies, such as IKur inhibition [126], might be viable against paroxysmal AF in different 
SQTS variants.   Whilst, as considered in section 4, there is some evidence for modest 
contractile deficiency in some SQTS patients, as this is likely to be secondary to the 
abbreviated repolarisation (except in SQT4-6, in which ICa,L is directly affected), correcting 
abnormal repolarisation might be expected to reverse such deficits.  
Although the orientation of this review is target- rather than drug- based, it is inescapable 
that the single agent that has showed most effectiveness in the treatment of the SQTS is 
(hydro)quinidine.  Recent cohort data have demonstrated a high level of effectiveness of 
hydroquinidine in preventing life-threatening proarrhythmic events during long term follow 
up of SQTS patients [127].  As noted in section 5.1, our simulation work on the class 1a 
agents quinidine and disopyramide, incorporating detailed binding kinetics of both drugs 
and supplementary effects against multiple targets, highlights dominant roles for both IKr 
and INa inhibition in helping restore repolarisation and refractoriness [109].  Although it is 
less potent against IKr/hERG than is quinidine [103;105], disopyramide may offer an 
ĂůƚĞƌŶĂƚŝǀĞǁŚĞƌĞƋƵŝŶŝĚŝŶĞ ?ƐŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐŝĚĞĞĨĨĞĐƚƐƉƌŽǀŝĚĞƉƌŽďůĞŵĂƚŝĐ ?ĂŶĚ ?ŽƌŝŶ
locations where quinidine has been withdrawn  [127;128].  Simplified simulations that do 
not incorporate detailed binding kinetics may not accurately reproduce clinical efficacy of 
such drugs [129].  We suggest that systematic in silico investigation of other SQTS variants 
would be beneficial incorporating both drug potency and the kind of binding kinetics that 
we have in SQT1 simulations [109], in order to establish clearly the target qualities that 
maximise effectiveness (and indeed limitations) of combined IKr and INa block in different 
SQTS variants.  IKs and/or IK1 inhibition at different potencies could then be systematically 
incorporated to establish clearly any additional benefit from synergistic IKr and IKs/IK1 block.  
It should be noted that other concomitant pharmacological actions have the potential to 
mitigate QT prolonging effects.  For example, propafenone is at least as potent against 
IKr/hERG as is quinidine and largely retains efficacy against the N588K SQT1 mutation 
[103;130].  However, it was found to be effective at treating AF in this SQT1 variant without 
normalizing the QT interval [32]. One may speculate that the known ICa,L inhibitory action of 
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propafenone [131;132] may have offset its IKr/hERG block, whilst its slow Na channel 
disassociation kinetics (as a class Ic agent; [96]) would nevertheless have prolonged post-
repolarisation refractoriness, extended ERP and the wavelength for re-entry.  Amiodarone, 
which affects multiple cellular targets [133], has been used with mixed success in SQTS 
patients [22].  Amiodarone was reported not to prolong QT interval in a patient with a hERG 
mutation [22] ďƵƚǁĂƐĞĨĨĞĐƚŝǀĞĐŽŵďŝŶĞĚǁŝƚŚɴ-blockade in protecting against malignant 
arrhythmia in a patient with SQTS of unknown genotype [134] and in silico studies have 
suggested potential effectiveness against some SQT2 and 3 mutations [135;136].  Further 
work is required to understand circumstances in which amiodarone may be of value in 
treating SQTS. 
Perhaps one of the most intriguing questions in respect of the SQTS is what underlies the 
syndrome in the substantial proportion of patients who have unsuccessfully undergone 
targeted genotyping?   The success of exome sequencing in identifying SQT8 [77] highlights 
(i) the value of exome (and potentially genome) sequencing in identifying novel causes of 
the syndrome (and thereby potentially novel therapeutic intervention points) and (ii) that 
new molecular culprits are likely to be surprising and upstream of electrogenic processes.   
Ultimately, the best treatments of SQTS, as for other heritable disorders, are likely to 
involve molecular genetic approaches to correct the underlying mutations.  However, such 
approaches are unlikely to be available in the short- to medium- term, making ICD use 
together with judiciously chosen pharmacology the approaches of choice for the condition. 
Finally, in addition to the peer-reviewed literature discussed in this article, available online 
resources on the SQTS include [137-139]. 
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SQT Variant Gene/gene 
product 
Channel (subunit) Mutation 
(amino-acid 
change) 
Gain/Loss of 
function 
SQT1 KCNH2 (hERG) IKr Į>SRUH-forming] 
sub-unit) 
N588K 
 
R1135H 
 
E50D 
 
I560T 
 
T618I  
 
S631A 
Gain-of-function 
 
Gain-of-function 
 
Gain-of-function 
 
Gain-of-function 
 
Gain-of-function 
 
Gain-of-function 
SQT2 KCNQ1 
(KCNQ1/KvLQT1) 
 
IKs ĮVXE-unit) V307L 
 
V141M 
 
R259H  
 
F279I 
Gain-of-function 
 
Gain-of-function 
 
Gain-of-function 
 
Gain-of-function 
 
SQT3 KCNJ2 (Kir2.1) IK1 D172N 
 
M301K 
 
E299V 
 
K346T 
Gain-of-function 
 
Gain-of-function 
 
Gain-of-function 
 
Gain-of-function 
SQT4  CACNA1C 
(CaV1.2) 
L-type ICa Į
subunit) 
A39V 
 
G490R 
 
R1973P 
Loss-of-function 
 
Loss-of-function 
 
Loss-of-function 
SQT5  CACNB2b 
ȕ2b subunit) 
L-type ICa (E2b 
subunit) 
S481L Loss-of-function 
SQT6 CACNA2D1 
 
L-type ICa  (Dį
subunit)
  
S755T Loss-of-function 
 
SQT7 SCN5A INa  ĮVXEXQLW R689H Loss-of-function 
?? 
 
SQT8 SLC4A3 Anion exchanger 
AE3 
R370H Loss-of-function 
 
 
Table 1.  List of known SQTS mutations. Effects of amino acid changes on protein function 
are detailed in the main text of section 3. ?? for SQT7 indicates conflicting evidence for gain- 
or loss- of function consequence of the mutation. 
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Figure Legends 
 
 
Figure 1 
Schematic diagram of cardiac ventricular action potential (AP) and the normal profiles of 
depolarising (inward) and repolarising (outward) currents (not to scale) that are known to 
be affected by SQT1-SQT7 genotyped variants of the SQTS.  The affected gene is shown in 
italics to the right of the respective ionic current. Table 1 contains a list of known SQTS 
mutations to these genes. 
 
Figure 2 
(A) Upper traces show guinea-pig ventricular myocyte APs recorded at 37
o
C (at a stimulation 
frequency of 1Hz) in a standard physiological control solution and in the presence of the 
hERG/IKr activator PD118057, to abbreviate repolarisation and hence mimic SQTS.  Lower 
traces show records of unloaded cell shortening (contraction) for the two APs, illustrating 
decreased contraction amplitude in the presence of PD118057. 
(B) A summary of arrhythmia mechanisms in the SQTS. All variants of the SQTS shorten the 
action potential duration (APD) and effective refractory period (ERP) - SQT1-3 through 
increased outward current, SQT4-7 through decreased inward current, and SQT8 through 
mechanisms that remain to be elucidated. These result in shortening of the QT interval. 
Heterogeneous APD shortening is a mechanism for increased transmural dispersion of 
repolarisation (TDR) which increases T wave amplitude. Increased TDR also increases 
dispersion of refractoriness, which increases susceptibility to unidirectional conduction 
block - a mechanism for initiation of re-entry. Furthermore, shortened APD reduces the 
excitation wavelength (WL) in tissue, which facilitates sustenance of re-entry (by reducing 
the substrate size necessary to sustain re-entry). 
 
 
